http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4398898

Outgoing Links

Predicate Object
contentType Journal Article|Research Support, Non-U.S. Gov't
endingPage 1844
issn 1532-1827
0007-0920
issueIdentifier 12
pageRange 1837-1844
publicationName British Journal of Cancer
startingPage 1837
bibliographicCitation Graat HCA, Witlox MA, Schagen FHE, Kaspers GJL, Helder MN, Bras J, Schaap GR, Gerritsen WR, Wuisman PIJM, van Beusechem VW. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. British Journal of Cancer. 2006 May 30;94(12):1837–44. doi: 10.1038/sj.bjc.6603189.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bfbe21a39d8060872c3c106da6ca1979
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fc1018596d46234abf7400765697cb04
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05b1fc906e4cadc632d7b0e196417167
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9f022522ad3e8aa369b6b8a73dda2b0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_215be99dab0c376b8cfab35127210d6e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4534b0f5bf4a81c78b49b2c0c7de5d7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_925be8a113b3fb35c6f0c29acfe101d2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e08b9f9964e4467e7536bdb34f003e2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be657d41e98f11ebca4af419cbe864f5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9764727bba5fff3ec3f4259caba67c2
date 2006-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/PMC2361338
https://pubmed.ncbi.nlm.nih.gov/16736005
https://doi.org/10.1038/sj.bjc.6603189
isPartOf https://portal.issn.org/resource/ISSN/0007-0920
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765
https://portal.issn.org/resource/ISSN/1532-1827
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
discusses http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0006784
http://id.nlm.nih.gov/mesh/M0004505
hasSubjectTerm http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112
http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_909600b8e3b7351dd9cadd0cca781e43
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9156

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129888650
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129347572
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128368395
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128423931
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129062757
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135728745
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136137642

Total number of triples: 50.